Daplyza Tablets

Daplyza Tablets – Advanced Protection for Diabetes and the Heart

Daplyza is a specialized metabolic medication containing Dapagliflozin, an SGLT2 inhibitor designed for comprehensive patient care. It is primarily indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. A major clinical benefit of Daplyza is its ability to reduce the risk of hospitalization for heart failure in diabetic patients with established cardiovascular disease or multiple risk factors. This makes it a vital tool for long-term health maintenance.

Beyond diabetes, Daplyza is indicated to reduce the risk of cardiovascular death and hospitalization in adults with chronic heart failure (NYHA class II-IV). It is particularly effective for those with a reduced ejection fraction. Furthermore, it is used to slow the progression of chronic kidney disease and reduce the risk of end-stage renal failure. The medication works by allowing the kidneys to remove excess glucose and sodium from the body through the urine. This action lowers blood sugar while also reducing the overall workload on the heart and kidneys. Regular once-daily oral administration provides consistent protection and helps improve the functional capacity of the patient.

• Treats type 2 diabetes and reduces heart failure risks.
• Indicated for chronic heart failure and chronic kidney disease.
• Reduces the risk of cardiovascular death and hospitalization.
• Available as: Tablets 5mg and 10mg.